Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).

Jin, Ran; Ogbomo, Adesuwa S; Accortt, Neil A; Lal, Lincy S; Bishi, Geetanjali; Sandschafer, Darcie; Goldschmidt, Jerome H

Jin, Ran; Ogbomo, Adesuwa S; Accortt, Neil A; Lal, Lincy S; Bishi, Geetanjali; Sandschafer, Darcie; Goldschmidt, Jerome H.

Afiliação

Jin R; Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.
Ogbomo AS; ConcertAI, Cambridge, MA, USA.
Accortt NA; Amgen Inc., Thousand Oaks, CA, USA.
Lal LS; ConcertAI, Cambridge, MA, USA.
Bishi G; ConcertAI, Cambridge, MA, USA.
Sandschafer D; Amgen Inc., Thousand Oaks, CA, USA.
Goldschmidt JH; Blue Ridge Cancer Care, Blacksburg, VA, USA.

Ther Adv Med Oncol ; 15: 17588359231182386, 2023.

Article em En | MEDLINE | ID: mdl-37360769

Palavras-chave

bevacizumab; bevacizumab-awwb; biosimilar; metastatic colorectal cancer; real-world outcomes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google